The recent surge in capital into niche pharmaceutical companies, particularly those focusing on groundbreaking therapies and complex drug development programs, has fueled what some are calling "High Roller Pharma." https://emilielclr928919.creacionblog.com/40077473/premium-stakeholder-pharma-a-hazardous-investment